Equities Analysts Issue Forecasts for SWTX Q1 Earnings

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) – Stock analysts at Wedbush dropped their Q1 2025 earnings per share estimates for shares of SpringWorks Therapeutics in a research report issued to clients and investors on Thursday, February 20th. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($0.84) per share for the quarter, down from their prior estimate of ($0.75). Wedbush currently has a “Outperform” rating and a $81.00 target price on the stock. The consensus estimate for SpringWorks Therapeutics’ current full-year earnings is ($2.05) per share. Wedbush also issued estimates for SpringWorks Therapeutics’ Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($2.81) EPS, FY2026 earnings at ($0.22) EPS and FY2027 earnings at $2.90 EPS.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its earnings results on Thursday, February 20th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). The firm had revenue of $61.55 million for the quarter, compared to the consensus estimate of $60.53 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%.

A number of other analysts have also weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $74.00 target price on shares of SpringWorks Therapeutics in a research note on Friday, February 21st. Guggenheim cut their price target on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Finally, Evercore ISI raised their price target on SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $71.50.

SpringWorks Therapeutics Stock Down 4.5 %

SWTX stock opened at $54.03 on Monday. The business’s fifty day simple moving average is $41.79 and its two-hundred day simple moving average is $37.96. SpringWorks Therapeutics has a twelve month low of $28.21 and a twelve month high of $62.00. The firm has a market cap of $4.05 billion, a price-to-earnings ratio of -15.53 and a beta of 0.81.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of SWTX. Huntington National Bank raised its stake in shares of SpringWorks Therapeutics by 38.2% during the 4th quarter. Huntington National Bank now owns 694 shares of the company’s stock worth $25,000 after buying an additional 192 shares during the period. AlphaQuest LLC grew its holdings in shares of SpringWorks Therapeutics by 70.2% during the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock worth $36,000 after purchasing an additional 414 shares during the period. Venturi Wealth Management LLC purchased a new position in shares of SpringWorks Therapeutics during the 4th quarter worth $45,000. State of Wyoming grew its holdings in shares of SpringWorks Therapeutics by 39.5% during the 4th quarter. State of Wyoming now owns 1,530 shares of the company’s stock worth $55,000 after purchasing an additional 433 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new position in SpringWorks Therapeutics during the 4th quarter valued at about $56,000.

Insiders Place Their Bets

In other news, COO Badreddin Edris sold 20,000 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total transaction of $839,400.00. Following the sale, the chief operating officer now owns 209,600 shares in the company, valued at approximately $8,796,912. The trade was a 8.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Bhavesh Ashar sold 1,016 shares of the business’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $61.19, for a total value of $62,169.04. Following the sale, the insider now owns 62,053 shares in the company, valued at $3,797,023.07. The trade was a 1.61 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 391,766 shares of company stock worth $21,499,996. 7.61% of the stock is owned by corporate insiders.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.